Aims-To assess the role of Ki67 immunoreactivity in predicting the clinical progress of hydatidiform mole. Methods-Tissue from 87 hydatidiform moles, 11 normal first trimester placentas, 11 normal term placentas and 17 spontaneous abortions were examined for expression of Ki67 antigen, using the monoclonal antibody MIBI. Results-Ki67 immunoreactivity was significantly higher in the tissue from normal first trimester placentas than in that from normal term placentas and spontaneous abortions. Among the 87 patients with hydatidiform moles studied, 20 developed persistent gestational trophoblastic disease and required subsequent treatment. There was no statistically significant difference in the Ki67 index between the 20 patients who developed persistent disease and those who did not. clonal antibodies against recombinant parts of the Ki67 antigen, designated MIB1 to 3, have been raised.8 The immunostaining pattern as well as the morphological and cell cycle distribution of MIB1 expression is identical with that of Ki67 and so can be regarded as a true Ki67 equivalent.89 Using a modified microwave oven pretreatment of the paraffin wax sections, it was possible to detect the antigen previously defined by Ki67 in routinely formalin fixed and paraffin wax embedded tissues.5 6
About 8% to 30% of patients with hydatidiform mole require chemotherapy after primary removal due to development of persistent gestational trophoblastic disease,' but there seem to be few useful indicators that can predict such progression. In particular, histological grading of hydatidiform moles does not show a correlation with the clinical outcome. 23 It is now widely accepted that tumour cell kinetics directly influence the clinical course of patients who have cancer. 45 The use of immunohistochemical methods has become a popular means of assessing the state of cellular proliferation in histological material, because it allows architectural and cytological features to be preserved and avoids the in vivo administration of thymidine analogues. 6 The diagnostic and prognostic value of Ki67 immunostaining in tumours has been well documented,67 but the drawback in the use of this antibody is that its application is restricted to fresh material as the epitope does not survive routine histopathological fixation in formaldehyde or alcohol. Recently, monoclonal antibodies against recombinant parts of the Ki67 antigen, designated MIB1 to 3, have been raised. 8 The immunostaining pattern as well as the morphological and cell cycle distribution of MIB1 expression is identical with that of Ki67 and so can be regarded as a true Ki67 equivalent.89 Using a modified microwave oven pretreatment of the paraffin wax sections, it was possible to detect the antigen previously defined by Ki67 in routinely formalin fixed and paraffin wax embedded tissues. 5 6 Studies on the status of cell proliferation in hydatidiform mole have been scanty. Our previous study on the expression of proliferating cell nuclear antigen (PCNA) in human trophoblastic disease using the monoclonal antibody PC 10 showed that the PCNA index was not useful for predicting the progression of molar pregnancies to persistent trophoblastic diseases.'0 As an extension of that work, the present study assesses the prognostic value of Ki67 index using the recently available monoclonal antibody MIBi. index was made by scoring positive nuclei/total number of counted nuclei in a minimum of 1000 trophoblastic cells in each case. Decidua, myometrium, fetal tissue and other tissues found in the sections were excluded from the analysis. The nuclei were scored as positive or negative without regard to staining intensity.
To ensure consistency of MIB1 staining between batches tissue from a colonic carcinoma was used as a known positive control in each batch. The experiment was repeated if there was any apparent fluctuation in the Ki67 index of this control. Negative controls were included by substituting TRISbuffered saline for the primary antibody. Trypsin and microwave pre-treatments were confirmed to be necessary in the preliminary study.
All the patients with partial or complete moles in this study were active parts of the cell cycle-that is, G2, and mitosis-but is absent in GO.17 18 This antibody has been used in a large number of studies of cell proliferation in human tissues with the aim of providing prognostic information in a range of tumour types. ' There was a significant difference between nd the the Ki67 indexes of the first trimester and ic indi-term placentas. This supports the previous findings that there was very active growth of ion of the trophoblast in the first trimester placentas, ns has and such villous trophoblast growth is much gists in diminished in term placenta.23 27 Thus Ki67 ly used expression seems to have a logical correlation 7 Ki67. with the proliferative activity in normal plaprotein centas. The Ki67 index in hydropic abortion, in all although lower than that for normal first G1, S, trimester placentas, was much higher than .:.Vj that of term placenta. These findings are similar to that found in a study comparing the PCNA immunoreactivity of hydropic abortions and first trimester placentas.2' This has been explained by the possibility that after fetal death the trophoblast is still viable and continues to function at a diminished level. The frequency with which persistent trophoblastic disease occurs after a molar gestation is dependent on the sensitivity of the follow up hCG assay, length of follow up, type of primary treatment, and terminology used in reporting sequelae.2529 Studies have shown that 8%-30% of patients with hydatidiform mole will require treatment some time after primary evacuation of the fetus.' The wide range in the percentage of patients treated reflects the different criteria used by various investigators as to what constitutes persistent disease. In this study, using our usual criteria for persistent gestational trophoblastic disease,"3 17-9% (7/39) of partial moles and 27% (13/48) of complete moles subsequently required treatment. These figures, though within the range reported, were higher than the expected local figures of 11 3% for partial mole and 17-8% for complete mole as found in previous study."3 The discrepancy is probably due to selection of cases because only cases with available paraffin wax blocks were included in this study. More objective assessment of clinical outcome, such as documentation of subsequent development of metastasis may be used in future studies on prognostic factors in gestational trophoblastic disease.
Most studies have found that histopathological grading of hydatidiform mole, including morphometric assessment of trophoblastic hyperplasia, has little predictive value for prognosis.2' Our previous study on PCNA also showed that PCNA could not predict the progression of molar pregnancies to persistent trophoblastic disease. 
